Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

ClinicalTrials.gov ID: NCT02843659

Public ClinicalTrials.gov record NCT02843659. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome

Study identification

NCT ID
NCT02843659
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
45 participants

Conditions and interventions

Interventions

  • BMS-931699 Drug
  • BMS-986142 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 17, 2016
Primary completion
Jul 23, 2017
Completion
Jul 23, 2017
Last update posted
Oct 3, 2018

2016 – 2017

United States locations

U.S. sites
17
U.S. states
14
U.S. cities
17
Facility City State ZIP Site status
St Joseph Heritage Healthcare Fullerton California 92835
Local Institution Palo Alto California 94304
Local Institution Sarasota Florida 34239
North Georgia Rheumatology Group Lawrenceville Georgia 30096
Clinical Pharmacology Study Group Worcester Massachusetts 01605
Local Institution Tupelo Mississippi 38801
Arthritis And Osteoporosis Associates, Pa Freehold New Jersey 07728
New Mexico Clinical Research & Osteoporosis Center Albuquerque New Mexico 87109
Local Institution Mineola New York 11501
Pmg Research Of Wilmington Llc Wilmington North Carolina 28401
Paramount Medical Research & Consulting, Llc Middleburg Heights Ohio 44130
Altoona Center For Clinical Research Duncansville Pennsylvania 16635-8406
Local Institution Philadelphia Pennsylvania 19104
Local Institution Wexford Pennsylvania 15090
Acme Research, Llc Orangeburg South Carolina 29118
West Tennessee Research Institute Jackson Tennessee 38305
Tekton Research Inc Austin Texas 78745

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02843659, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 3, 2018 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02843659 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →